Do analysts prefer AIXC or CUE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend AIXC or ONCY?

Oncolytics Biotech has a consensus price target of $8.50, suggesting a potential upside of 823.91%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Oncolytics Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has preferable earnings & valuation, AIXC or ONCY?

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is AIXC or ONCY more profitable?

Qualigen Therapeutics' return on equity of -771.52% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A -771.52% -79.52% Oncolytics Biotech N/A -2,185.97% -321.54%

Do analysts rate ALDX or AIXC?

Aldeyra Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 189.47%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ALDX or AIXC?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is ALDX or AIXC more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Qualigen Therapeutics N/A -771.52% -79.52%

Which has preferable earnings and valuation, PLYX or AIXC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A N/A N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is PLYX or AIXC more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Qualigen Therapeutics N/A -771.52% -79.52%

Which has preferable valuation & earnings, KLRS or AIXC?

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A Qualigen Therapeutics N/A N/A -$16.97M -$6.47 N/A

Is KLRS or AIXC more profitable?

Kalaris Therapeutics' return on equity of -72.78% beat Qualigen Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -72.78% -43.49% Qualigen Therapeutics N/A -771.52% -79.52%

Does the media favor KLRS or AIXC?

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Qualigen Therapeutics (AIXC) Competitors

$1.19 -0.10 (-7.75%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 0.00 (-0.42%)

As of 06:59 PM Eastern

Compare

AIXC vs. CUE, ONCY, ALDX, PLYX, and KLRS

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include Cue Biopharma (CUE), Oncolytics Biotech (ONCY), Aldeyra Therapeutics (ALDX), Polaryx Therapeutics (PLYX), and Kalaris Therapeutics (KLRS). These companies are all part of the "pharmaceutical products" industry.

How does Qualigen Therapeutics compare to Cue Biopharma?

Qualigen Therapeutics (NASDAQ:AIXC) and Cue Biopharma (NASDAQ:CUE) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Qualigen Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

In the previous week, Qualigen Therapeutics had 2 more articles in the media than Cue Biopharma. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 0 mentions for Cue Biopharma. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Cue Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Cue Biopharma	Neutral

Qualigen Therapeutics has higher earnings, but lower revenue than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Cue Biopharma	$27.47M	3.98	-$26.60M	-$5.58	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Cue Biopharma	-59.65%	-98.30%	-53.69%

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 14.6% of Cue Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cue Biopharma beats Qualigen Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Oncolytics Biotech?

Qualigen Therapeutics (NASDAQ:AIXC) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

Qualigen Therapeutics' return on equity of -771.52% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Qualigen Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Qualigen Therapeutics had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 0 mentions for Oncolytics Biotech. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Oncolytics Biotech'saverage media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Oncolytics Biotech	Neutral

Oncolytics Biotech is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Oncolytics Biotech has a consensus price target of $8.50, suggesting a potential upside of 823.91%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Oncolytics Biotech beats Qualigen Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Aldeyra Therapeutics' return on equity of -57.34% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aldeyra Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 189.47%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Qualigen Therapeutics had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 0 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.75 beat Qualigen Therapeutics' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
Qualigen Therapeutics	Neutral

Aldeyra Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Summary

Aldeyra Therapeutics beats Qualigen Therapeutics on 10 of the 12 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap manufacturing companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Polaryx Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 316.67%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Polaryx Therapeutics is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polaryx Therapeutics' return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Qualigen Therapeutics	N/A	-771.52%	-79.52%

3.2% of Qualigen Therapeutics shares are held by institutional investors. 1.2% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

In the previous week, Qualigen Therapeutics had 2 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 0 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Qualigen Therapeutics	Neutral

Summary

Polaryx Therapeutics beats Qualigen Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Kalaris Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Kalaris Therapeutics' return on equity of -72.78% beat Qualigen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Qualigen Therapeutics	N/A	-771.52%	-79.52%

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for Qualigen Therapeutics and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Qualigen Therapeutics	N/A	N/A	-$16.97M	-$6.47	N/A

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kalaris Therapeutics currently has a consensus target price of $15.60, suggesting a potential upside of 254.55%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Kalaris Therapeutics is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Kalaris Therapeutics beats Qualigen Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIXC vs. The Competition

Export

Metric	Qualigen Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$26.10M	$936.65M	$4.30B	$12.24B
Dividend Yield	N/A	4.84%	10.93%	5.82%
P/E Ratio	N/A	1.47	22.06	23.98
Price / Sales	N/A	112.40	113.55	120.62
Price / Cash	N/A	20.06	40.77	54.51
Price / Book	-1.59	7.78	15.92	6.41
Net Income	-$16.97M	-$4.18M	$115.37M	$337.14M
7 Day Performance	-16.78%	1.17%	-1.28%	-0.48%
1 Month Performance	-7.75%	1.96%	-2.41%	0.49%
1 Year Performance	N/A	52.77%	11.29%	28.16%

Qualigen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIXC Qualigen Therapeutics	0.3292 of 5 stars	$1.19 -7.8%	N/A	N/A	$26.10M	N/A	N/A	50	Positive News
CUE Cue Biopharma	0.087 of 5 stars	$26.73 +11.9%	N/A	-95.3%	$112.27M	$32.73M	N/A	60
ONCY Oncolytics Biotech	1.6938 of 5 stars	$0.93 -1.9%	$8.50 +812.2%	+47.7%	$111.21M	N/A	N/A	30
ALDX Aldeyra Therapeutics	2.9946 of 5 stars	$1.83 +2.8%	$5.50 +200.5%	-34.5%	$110.39M	N/A	N/A	10
PLYX Polaryx Therapeutics	3.6266 of 5 stars	$2.31 +0.9%	$10.00 +332.9%	N/A	$108.64M	N/A	N/A	11	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIXC) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qualigen Therapeutics (AIXC) Competitors

AIXC vs. CUE, ONCY, ALDX, PLYX, and KLRS

How does Qualigen Therapeutics compare to Cue Biopharma?

Summary

How does Qualigen Therapeutics compare to Oncolytics Biotech?

Summary

How does Qualigen Therapeutics compare to Aldeyra Therapeutics?

Summary

How does Qualigen Therapeutics compare to Polaryx Therapeutics?

Summary

How does Qualigen Therapeutics compare to Kalaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIXC vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qualigen Therapeutics (AIXC) Competitors

AIXC vs. CUE, ONCY, ALDX, PLYX, and KLRS

How does Qualigen Therapeutics compare to Cue Biopharma?

Which has more volatility and risk, AIXC or CUE?

Does the media prefer AIXC or CUE?

Which has better valuation & earnings, AIXC or CUE?

Do analysts prefer AIXC or CUE?

Is AIXC or CUE more profitable?

Do insiders and institutionals have more ownership in AIXC or CUE?

Summary

How does Qualigen Therapeutics compare to Oncolytics Biotech?

Is AIXC or ONCY more profitable?

Which has more volatility & risk, AIXC or ONCY?

Do insiders and institutionals hold more shares of AIXC or ONCY?

Does the media prefer AIXC or ONCY?

Which has preferable earnings & valuation, AIXC or ONCY?

Do analysts recommend AIXC or ONCY?

Summary

How does Qualigen Therapeutics compare to Aldeyra Therapeutics?

Is ALDX or AIXC more profitable?

Which has better valuation and earnings, ALDX or AIXC?

Do insiders and institutionals hold more shares of ALDX or AIXC?

Do analysts rate ALDX or AIXC?

Does the media favor ALDX or AIXC?

Which has more volatility and risk, ALDX or AIXC?

Summary

How does Qualigen Therapeutics compare to Polaryx Therapeutics?

Do analysts prefer PLYX or AIXC?

Is PLYX or AIXC more profitable?

Do institutionals & insiders hold more shares of PLYX or AIXC?

Which has preferable earnings and valuation, PLYX or AIXC?

Does the media refer more to PLYX or AIXC?

Summary

How does Qualigen Therapeutics compare to Kalaris Therapeutics?

Which has more volatility & risk, KLRS or AIXC?

Is KLRS or AIXC more profitable?

Does the media favor KLRS or AIXC?

Which has preferable valuation & earnings, KLRS or AIXC?

Do institutionals and insiders hold more shares of KLRS or AIXC?

Do analysts rate KLRS or AIXC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIXC vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools